JHS Svendgaard Laboratories Limited — Others, 11-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

JHS Svendgaard Laboratories Limited has announced a board meeting to review the Statement of Deviation in the utilization of funds raised through a preferential issue. The company raised ₹29.99 crore, comprising ₹19.99 crore from equity shares and ₹9.99 crore from fully convertible warrants. For the quarter ending December 31, 2024, there was no deviation in the use of these funds, confirming adherence to original objectives. This update underlines financial discipline and effective fund management, likely fostering a positive outlook among investors as operational performance remains aligned with strategic goals.